Britain Gets Cancer 'Wonder Drug'
Posted on: Monday, 31 July 2006, 15:00 CDT
A drug designed to attack cancer by inhibiting a key enzyme to signals cells to multiply became available Monday across Britain.
Already licensed by the U.S. Food and Drug Administration, Sutent (sunitinib) has been licensed in Britain to treat two kidney cancer and gastrointestinal stromal tumors, while early trials suggest it might also be effective against breast, lung and pancreatic cancers, The Times of London reported Monday.
The new pharmaceutical, manufactured by Pfizer Inc., also deprives tumors of specific nutrients they need by preventing the growth of blood vessels, becoming the first drug to combine both modes of action, the newspaper said.
Sutent will initially cost each patient about $4,500 monthly, therefore probably limiting its use.
Source: United Press International
Related Articles
- The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education
- WHO Programme for International Drug Monitoring
- Abnormal Drug Response: Opportunities for Risk Reduction Through Pharmacogenetics
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
- 12 Freed for Texas Drug Bust Appeals
- 12 Freed in Appeal of Texas Drug Busts
- 'Rapid Detox' Breaks Drug Habits Quickly
- Advisers: Arthritis Drug Not Too Risky
- 55 Charged With Selling Drug Gear Online
- ADHD Drug Prescriptions Vary by ZIP Code
 |
 |
User Comments (0)
RSS Feeds